Invivogen
Menu

TDB VacciGrade™

TDB VacciGrade™ Unit size Cat. code Docs Qty Price
Vaccine Adjuvant - Mincle agonist
2 mg
vac-tdb
+-
$391.00

Mincle agonist - Synthetic analog of the cord factor

Trehalose-6,6-dibehenate (TDB) is a non-toxic synthetic analogue of the mycobacterial cell wall component trehalose 6,6’ dimycolate (TDM, also known as cord factor).

TDB was shown to rely on the C-type lectin Mincle and the signaling molecules Syk and Card9 to trigger innate immunity.

TDB VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.

TDB VacciGrade™ is for research use only, not for use in humans.

Back to the top

Specifications

Specificity: Th1 response.

Quality: Sterile, Endotoxin level < 5 EU/mg.

CAS number: 66758-35-8.

Formula: C56H106O13.

Molecular weight: 987.43.

Working concentration: 1 - 100 µg/mouse.

Quality control:

  • TDB VacciGrade™ is a preclinical grade.
  • It is prepared under strict aseptic conditions and is tested for the presence of endotoxins.
  • TDB VacciGrade™ is guaranteed sterile and its endotoxin level is <5 EU/mg.
Back to the top

Contents

TDB VacciGrade™ is provided as a sterile powder.

  • 2 x 1 mg TDB VacciGrade™
  • 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

TDB VacciGrade™ is shipped at room temperature.

Store at -20°C.

Lyophilized product is stable for 1 year at -20°C.

Back to the top

Description

Trehalose-6,6-dibehenate (TDB) is a non-toxic synthetic analogue of the mycobacterial cell wall component trehalose 6,6’ dimycolate (TDM, also known as cord factor).

TDB was shown to rely on the C-type lectin Mincle and the signaling molecules Syk and Card9 to trigger innate immunity [1]. Incorporation of TDB combined with the synthetic amphiphilic cationic lipid compound dimethyldioctadecylammonium (DDA) into liposomes, known as CAF01, has been shown to strongly enhance cellular and humoral responses against a protein antigen [2]. Adjuvanticity of the cationic DDA:TDB liposomes and sustained protection against disease challenge has been demonstrated in particular with a tuberculosis vaccine candidate [3, 4], and has good potential for application in a range of other diseases [5].

 

1. Schoenen H, et al., 2010. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol. ;184(6):2756-60.
2. Davidsen J, et al., 2005. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 1718(1-2):22-31.
3. Holten-Andersen L. et al., 2004. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun. 72(3):1608-17.
4. Christensen D. et al., 2011. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines. 10(4):513-21.
5. Agger EM. et al., 2008. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 3(9):e3116.

Back to the top

Citations

Load more

Customer Service
& Technical Support

CAPTCHA
In order to prevent automated spam submissions, please answer the following question:
5 + 11 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Shopping cart is empty